ANI Pharmaceuticals Shares Climb on Outlook Raise as Sales Surge

Dow Jones

Aug 08

By Dean Seal

Shares of ANI Pharmaceuticals soared after the company raised its full-year guidance on the back of strong sales and profit gains in the second quarter.

The stock was up 18.5% at $81.79 in premarket trading. Shares had already risen 25% year-to-date when the market closed Thursday.

The specialty pharmaceutical company said it now expects adjusted earnings of $6.98 to $7.35 a share on $818 million to $843 million in revenue for the year. It had previously targeted $6.27 to $6.62 a share on $768 million to $793 million in revenue.

The lift comes after a record-setting quarter, Chief Executive Nikhil Lalwani said.

ANI swung to a second-quarter profit of $8.1 million, or 36 cents a share, from a loss of $2.7 million, or 14 cents a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $1.80 a share. Analysts polled by FactSet had been expecting $1.41 a share.

Revenue surged 53% to $211.4 million, ahead of analyst forecasts for $190 million, according to FactSet. Gains were seen across its rare disease, brands and generic portfolios.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

August 08, 2025 07:37 ET (11:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557521882"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557521882\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557521882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557521882","market":"other","top_or_hot":-1,"title":"ANI Pharmaceuticals Shares Climb on Outlook Raise as Sales Surge","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of ANI Pharmaceuticals soared after the company raised its full-year guidance on the back of strong sales and profit gains in the second quarter. \n</p>\n<p>\n  The stock was up 18.5% at $81.79 in premarket trading. Shares had already risen 25% year-to-date when the market closed Thursday. \n</p>\n<p>\n  The specialty pharmaceutical company said it now expects adjusted earnings of $6.98 to $7.35 a share on $818 million to $843 million in revenue for the year. It had previously targeted $6.27 to $6.62 a share on $768 million to $793 million in revenue. \n</p>\n<p>\n  The lift comes after a record-setting quarter, Chief Executive Nikhil Lalwani said. \n</p>\n<p>\n  ANI swung to a second-quarter profit of $8.1 million, or 36 cents a share, from a loss of $2.7 million, or 14 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.80 a share. Analysts polled by FactSet had been expecting $1.41 a share. \n</p>\n<p>\n  Revenue surged 53% to $211.4 million, ahead of analyst forecasts for $190 million, according to FactSet. Gains were seen across its rare disease, brands and generic portfolios. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 08, 2025 07:37 ET (11:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANI Pharmaceuticals Shares Climb on Outlook Raise as Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANI Pharmaceuticals Shares Climb on Outlook Raise as Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-08 19:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of ANI Pharmaceuticals soared after the company raised its full-year guidance on the back of strong sales and profit gains in the second quarter. \n</p>\n<p>\n  The stock was up 18.5% at $81.79 in premarket trading. Shares had already risen 25% year-to-date when the market closed Thursday. \n</p>\n<p>\n  The specialty pharmaceutical company said it now expects adjusted earnings of $6.98 to $7.35 a share on $818 million to $843 million in revenue for the year. It had previously targeted $6.27 to $6.62 a share on $768 million to $793 million in revenue. \n</p>\n<p>\n  The lift comes after a record-setting quarter, Chief Executive Nikhil Lalwani said. \n</p>\n<p>\n  ANI swung to a second-quarter profit of $8.1 million, or 36 cents a share, from a loss of $2.7 million, or 14 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.80 a share. Analysts polled by FactSet had been expecting $1.41 a share. \n</p>\n<p>\n  Revenue surged 53% to $211.4 million, ahead of analyst forecasts for $190 million, according to FactSet. Gains were seen across its rare disease, brands and generic portfolios. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 08, 2025 07:37 ET (11:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2557521882","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557521882","pubTimestamp":1754653020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ANI Pharmaceuticals soared after the company raised its full-year guidance on the back of strong sales and profit gains in the second quarter.The stock was up 18.5% at $81.79 in premarket trading. Shares had already risen 25% year-to-date when the market closed Thursday.The specialty pharmaceutical company said it now expects adjusted earnings of $6.98 to $7.35 a share on $818 million to $843 million in revenue for the year. It had previously targeted $6.27 to $6.62 a share on $768 million to $793 million in revenue.The lift comes after a record-setting quarter, Chief Executive Nikhil Lalwani said.ANI swung to a second-quarter profit of $8.1 million, or 36 cents a share, from a loss of $2.7 million, or 14 cents a share, in the same quarter a year earlier.Stripping out one-time items, adjusted earnings were $1.80 a share. Analysts polled by FactSet had been expecting $1.41 a share.Revenue surged 53% to $211.4 million, ahead of analyst forecasts for $190 million, according to F","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"随着销售额激增，ANI Pharmaceuticals股价因前景上调而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of ANI Pharmaceuticals soared after the company raised its full-year guidance on the back of strong sales and profit gains in the second quarter. \n\n\n  The stock was up 18.5% at $81.79 in premarket trading. Shares had already risen 25% year-to-date when the market closed Thursday. \n\n\n  The specialty pharmaceutical company said it now expects adjusted earnings of $6.98 to $7.35 a share on $818 million to $843 million in revenue for the year. It had previously targeted $6.27 to $6.62 a share on $768 million to $793 million in revenue. \n\n\n  The lift comes after a record-setting quarter, Chief Executive Nikhil Lalwani said. \n\n\n  ANI swung to a second-quarter profit of $8.1 million, or 36 cents a share, from a loss of $2.7 million, or 14 cents a share, in the same quarter a year earlier. \n\n\n  Stripping out one-time items, adjusted earnings were $1.80 a share. Analysts polled by FactSet had been expecting $1.41 a share. \n\n\n  Revenue surged 53% to $211.4 million, ahead of analyst forecasts for $190 million, according to FactSet. Gains were seen across its rare disease, brands and generic portfolios. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 08, 2025 07:37 ET (11:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}